아포지 테라퓨틱스(APGE)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $134.55 (+0.07%), 시가총액 $6.21B, 52주 범위 $34.65 ~ $92.20.
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial
아포지 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
아포지 테라퓨틱스의 현재 주가는 $134.55 (+0.07%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
아포지 테라퓨틱스의 시가총액은 약 $6.21B입니다.
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary dise